PPT-SOF Tactical Tourniquet

SOFTT OneHanded Application to an Arm Step 1 Open the tourniquet exposing the loop of webbing Grasp the running end of the webbing near the buckle and slide the tourniquet over the injured extremity. . Tactical Combat Casualty Care. for Medical Personnel. 03 June 2015. DESCRIBE . the differences between MEDEVAC and CASEVAC. DESCRIBE. the differences between Tactical Field Care and Tactical Evacuation Care. NWS Alaska. Sea Ice Program. Kathleen Cole. Sea Ice Program Leader. National Weather Service. Anchorage, Alaska. for. Sea Ice Workshop. 19 September 2011. The “other” stuff we do…. Events that require Ice Desk assistance. Guideline Change 14-02. : Optimizing. Tourniquet . Use in TCCC . Interim Change Slides. 28 October 2014. . Care Under Fire. Care Under Fire. Guidelines. 7. Stop life-threatening external hemorrhage if tactically feasible:. . Tourniquets and . Hemostatic. Dressings. The Number One. Medical Priority for Initial Management of Trauma Victims. Early control of severe hemorrhage is critical.. Prior to TCCC and effective battlefield tourniquets, extremity hemorrhage was the most frequent cause of . ADJUST SHOULDER STRAPS SO FRONT OF VEST IS COMFORTABLE WHEN YOU SIT. NOTE: IF EXCESS STRAP IS HANGING OUT OF SHOULDER SLEEVE CUT IT BETWEEN ONE OF THE SEW LINES. PROPER FIT AT NECK. (2) ADMIN POCKETS WITH. 400/100 mg . qd. N = 500. N = 100. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 4, 5 or 6. Naïve or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. Micah Reece. *A caveat. As we’ve learned, pneumatic tourniquets play an important role in regional/Bier blocks but such use is outside the scope of this paper as the assigned topic is . INTRAoperative. 400/100/100 mg QD. N = 501. N = 440. W8. SOF/VEL 400/100 mg QD. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. Treatment-naïve or . IFN-experienced. Compensated cirrhosis **. allowed . Dr S . Parthasarathy. MD DA DNB PhD Dip. software statistics FICA . Definition . A tourniquet is a constricting or compressing device used to . control venous . and arterial circulation to an extremity for a period of . in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. 400/100/100 mg QD. N = 263. N = 152. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. NS5A inhibitor-experienced . for ≥ 4 weeks (exclusion if . discontinued due to an adverse. Randomisation. 1 : 1. 18-70 years. HCV genotype 1. Naïve or pre-treated. with IFN-based regimen. No cirrhosis. HCV RNA ≥ . 10.000 . IU. /ml. No prior therapy with PI. No HBV or HIV co-infection. OPTIMIST-1 Study: SMV SOF for genotype 1. . Tactical Evacuation Care. OBJECTIVES. DESCRIBE . the differences between MEDEVAC and CASEVAC. DESCRIBE. the differences between Tactical Field Care and Tactical Evacuation Care. DESCRIBE. . the additional assets that may be available for airway . ≥ 18 years. Chronic HCV infection. Genotype 1 or 4. HCV RNA > 10 000 IU/ml. Treatment-naïve or pre-treated. w. ith PEG-IFN ± RBV. Cirrhosis (> 14.5 . kPa. on . FibroScan. ). Portal hypertension or liver .